Background: Assessment of clinical benefit of systemic treatments of rare diseases including gastroenteropancreatic neuroendocrine tumours (GEP-NET) is challenging. Recently several tools have been developed to grade the clinical benefit of cancer drugs. The European Society for Medical Oncology (ESMO) has developed the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS). The American Society of Clinical Oncology (ASCO) has developed and revised the ASCO framework consisting of the Net Health Benefit (NHB) score juxtaposed against the costs of the treatment. In this review, we graded systemic treatments for GEP-NET patients with both frameworks.
Introduction
Neuroendocrine tumours are rare malignancies with an incidence of 3.5/100 000 per year and a prevalence of 21.6/100 000 in the last decade [1] . Median survival time is 77 months in patients with regional and 24 months in patients with distant metastatic pancreatic neuroendocrine tumour (pNET) and 105 months and 56 months in case of regional and distant metastatic intestinal NET disease, respectively [2] . Gastroenteropancreatic neuroendocrine tumours (GEP-NET) patients are frequently metastasized at the time of initial diagnosis. Surgery is the only curative treatment. Non-curative systemic treatment options include somatostatin analogues (SSA), chemotherapy, targeted agents and peptide receptor radionuclide therapy (PRRT) with variable, limited success [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] .
Ideally, in clinical trials investigating novel drugs, the primary aim should be to study end points such as overall survival (OS), quality of life (QoL) and treatment toxicity. However, for trials investigating new agents in GEP-NET patients, survival analysis can be challenging as the prolonged (natural) course of the disease often results in trials, allowing crossover towards the experimental arm, which influences OS. Crossover to the experimental arm or to second-line therapies has impact on OS data [13] . Therefore, progression-free survival (PFS) was recommended as a feasible and relevant primary end point for both phase II and III trials in GEP-NET, by the expert consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting [13] .
Recently, among others, ESMO has developed a validated and reproducible tool to assess the magnitude of clinical benefit for drugs for solid tumours, the ESMO-MCBS [14] . The American Society of Clinical Oncology (ASCO) developed the ASCO framework for solid tumours and haematological malignancies consisting of the Net Health Benefit (NHB) score juxtaposed against the costs of the treatment [15, 16] . Both tools have been applied in several solid malignancies [14] [15] [16] [17] [18] . However, the ASCO framework was assessed only in a few studies. Treatments for GEP-NET are not yet evaluated using the tools. In this review, we therefore investigated the value of current systemic antitumor treatments for GEP-NET patients and their eligibility for grading with both ESMO-MCBS and NHB-ASCO-F.
Methods

Search strategy
For detailed description of methods, see supplementary Appendix S1, available at Annals of Oncology online. In brief, trials were searched between 1 August 2015 and 31st January 2016, in the databases PubMed and EMBASE. The articles that were found were screened using the title and abstract to select trials published in the English language and comparing systemic treatment modalities for the treatment of GEP-NET in humans. Furthermore, the reference lists of national and international guidelines that included trials and conference abstracts were reviewed for additional relevant articles.
Selection criteria for trials
Comparative trials investigating systemic antitumor treatment for welldifferentiated GEP-NET patients were analysed. Studies in patients with grade 3 neuroendocrine neoplasms were not included. Criteria for assessment are summarized in supplementary Table S1 , available at Annals of Oncology online. Trials were selected if at least 50% of participants were diagnosed with GEP-NET, and the other participants had a NET of unknown or other origin. Abstracts were not included.
ESMO-MCBS and the NHB-ASCO-F
ESMO-MCBS grades, in the non-curative setting, range from 1 to 5, with grades 4 and 5 representing meaningful clinical benefit [14] . The NHB-ASCO-F ranges from À20 to 180, with a higher score representing a better score, and no cut-off value was provided to define clinical benefit [15, 16, 18] . All relevant comparative trials were assessed according to both tools. Relevant trials that did not meet all criteria as mentioned in supplementary Table S1 , available at Annals of Oncology online, were assessed separately, based on the available data.
Assessment of trials
Four members from all Dutch European Neuroendocrine Tumor Society (ENETS) centres of excellence independently scored the trials according to the ESMO-MCBS and the NHB-ASCO-F. After obtaining scores of these assessors, we noticed a wide variation in results. During a consensus meeting, additional agreements were defined. Next, trials were assessed again according to the additional agreements. The number of trials to which the same score was awarded between three or four assessors was registered after each of the two scoring sessions. Two phase III trials were published after the consensus meeting and were assessed according our agreements [8, 12] . Therefore, an additional assessment session was not necessary for these trials.
Results
Trial selection and characterization
The primary search strategy yielded 1942 potentially relevant papers, of which 1676 remained when duplicates were discarded (supplementary Figure S1 , available at Annals of Oncology online). After screening the title and abstract, 223 papers were preselected evaluating systemic antitumor treatment for GEP-NET patients.
Thirty-nine papers of which 35 comparative trials in GEP-NET patients were described were selected for further analysis. Nine trials fulfilled all criteria as summarized in supplementary Table  S1 , available at Annals of Oncology online, and were assessable according to the ESMO-MCBS and the NHB-ASCO-F (Table 1 ) [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Only one trial, the RADIANT-4, described in its protocol that crossover was not allowed [10, 11] . None of the trials investigated adjuvant treatment in GEP-NET or had a curative intent.
The other 26 comparative trials, investigating systemic treatment in GEP-NET patients, did not meet all criteria for assessment with both tools (supplementary Table S1 , available at Annals of Oncology online), or evaluated participants of whom less than 50% had a GEP-NET. Main difficulties for assessment with the tools were summarized in supplementary Figure S2 , available at Annals of Oncology online. As currently used national and international guidelines are based on these trials, we analysed them separately with the available data (supplementary Appendix S2 and Table S2 , available at Annals of Oncology online).
Assessment according to the ESMO-MCBS
Six trials were assessable with the ESMO-MCBS. The calculated score ranged from 2 to 3 corresponding with a low level of clinical benefit. RADIANT-3 and RADIANT-4 analysed everolimus versus placebo in pNET and non-functional advanced NET, respectively [9] [10] [11] . Application of ESMO-MCBS for RADIANT-3 and RADIANT-4 resulted in a preliminary score of 3 reflecting a longer PFS. A hazard ratio (HR) 0.65 with a lower limit of the 95% confidence interval for PFS determined the preliminary score. No significant difference in important adverse events as compared with the placebo control arm was detected. QoL of everolimus in pNET patients was reported in a recent abstract that described a single-arm phase IV study, carried out in patients who started with everolimus [19] . After 6 months, no improvement in QoL was detected. Because this was a single-arm study and the ESMO-MCBS could only be applied to comparative outcome studies, the preliminary score of the RADIANT-3 will not be downgraded, despite lack of improvement of QoL, when these data are published in a full report. QoL of RADIANT-4 trial was reported in a post hoc analysis and recently published [11] . No improvement of QoL by everolimus versus the control arm was demonstrated. Therefore, the preliminary score of the RADIANT-4 was downgraded to a final score 2. The NETTER-1 trial investigated 177 Lu-dotatate with octreotide LAR versus octreotide LAR alone in patients with metastatic midgut NET [8] . The calculated ESMO-MCBS score was 3, which implies a longer PFS in the intervention group as compared with control arm. Furthermore, there was no significant difference in important adverse events as compared with the control arm and no QoL data were documented. In the CLARINET trial, GEP-NET patients or patients with NET of unknown origin were treated with lanreotide in the intervention arm versus placebo in the control arm [3] . This trial showed an improvement in PFS. Data of QoL did not show an improvement in QoL for the intervention group, resulting in a score of 2. In the PROMID trial, patients with a metastasized midgut NET were randomized between octreotide LAR and placebo [7] . Further enrolment was stopped after inclusion of 85 patients instead of the planned 162 patients, because of observed positive effects of octreotide LAR on tumour growth and a slow recruitment rate. This trial resulted in an ESMO-MCBS score of 2. The trial reported by Raymond et al. analysed sunitinib versus placebo in patients with progressive, advanced pNET [6] . Application of ESMO-MCBS resulted in a score of 2. An improvement in PFS was shown. Because reported QoL data did not show improvement, the preliminary score of 3 had to be downgraded one point. This trial had an early closure after randomization of 171 patients, as observed and recommended by the safety monitoring board due to more serious adverse events and a higher frequency of death in the placebo group as well as a difference in PFS favouring sunitinib. The trial analysing SSA and interferon versus SSA and bevacizumab, in advanced NET patients with progression or other poor prognostic features, showed no significant difference in its primary end point PFS [12] . The RADIANT-2 analysed everolimus with long acting octreotide in advanced NET tumour patients associated with carcinoid syndrome [5] . The PFS with an HR of 0.77 (0.59-1.00) did not show a statistically significant clinical benefit. The trial analysing capecitabine and streptozocin with or without cisplatin did also not show a statistically significant clinical benefit [4] . Furthermore, in these trials, no improvement in toxicity, QoL or OS was seen, and therefore the ESMO-MCBS was not applicable. Consensus in the ESMO-MCBS score was reached in two of six trials after the first scoring session [3] [4] [5] [6] [7] [9] [10] [11] . The variation in awarded scores was related to differences in interpretation of data, like the significance of the primary end point, and adjustment of the preliminary score for lack of improvement in QoL. After the second scoring session, consensus was reached in four of six trials [3] [4] [5] [6] [7] [9] [10] [11] .
Assessment according to the NHB-ASCO-F
Nine trials were assessable for the NHB-ASCO-F [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . The CBS varied from 0 to 63.8. In the trial reported by Raymond et al. and the RADIANT-3 and RADIANT-4 trials, the treatment arm experienced more adverse events, resulting in a toxicity score of À5 and À20, respectively [6, [9] [10] [11] . Bonus points were awarded for long-term disease control; if at a time point that was twice the median PFS for the control regimen, the percentage of patients having PFS was at least 50% higher for the intervention arm compared with the control arm, to the trial reported by Raymond et al., PROMID-trial, RADIANT-4, RADIANT-3 and the NETTER-1 [6] [7] [8] [9] [10] [11] .
No consensus was obtained for the score of the trials assessed by the NHB-ASCO-F after two scoring sessions. This was generally related to discrepancies in interpretation of toxicity score. Finally, after an additional discussion in four trials, consensus was obtained for NHB and in five trials consensus was reached for the CBS and bonus points.
Discussion
To define the clinical benefit of systemic antitumor treatment in GEP-NET patients, we systematically applied the ESMO-MCBS and the NHB-ASCO-F to relevant trials. Six out of 35 trials fulfilled all requirements to be assessed with the ESMO-MCBS resulting in an ESMO-MCBS score of 2 or 3, while 9 trials could be assessed with the NHB-ASCO-F and resulted in scores between 37.6 and 57.4. No clear cut-off value to define clinical benefit with the ASCO framework was provided [15, 16] . None of the trials that were included in our analysis could demonstrate a meaningful clinical benefit according to the employed tools. The ESMO-MCBS scores were generally lower than in other tumour types, like metastasized breast or colorectal cancer [14, 17] . In more common tumour types, sufficient numbers of patients can be included in trials powered to detect a difference in OS between the intervention and control group. In NET, such large trials are scarce. In addition, OS difference detection is challenging in NET patients. Therefore, PFS is a frequently used primary end point in NET trials. An improvement in PFS has less impact compared with OS in the ESMO-MCBS scores and the NHB-ASCO-F. Furthermore, none of the assessable trials in GEP-NET showed an improvement in QoL or less toxicity as compared with the control arm. Therefore, these outcomes did not result in an upgrade of the preliminary score in the ESMO-MCBS.
Ideally, OS and QoL should be the primary end points of all trials with new drugs [20] . This is challenging in NET. Reasons for this include the heterogeneous patient population, the long natural course of the disease and the wide variability of subsequent lines of therapy after progression. The heterogeneity of the patients composing the NET population is important to take into account. This illustrates the importance of well-defined inclusion criteria. The eligibility criteria of the RADIANT-2 trial included patients with serotonin producing NET and progressive, low-or intermediate-grade and advanced disease [5] . Despite these clear criteria, still large variation in patient and tumour characteristics between patients exists. Despite the randomized design of the trial, this could have influenced PFS.
Current guidelines for GEP-NET antitumour treatment are based on clinical trials and on expert opinion. These guidelines influence our daily clinical practice. Therefore, we also assessed trials that could not be fully assessed by the ESMO-MCBS and ASCO framework (supplementary Table S2 , available at Annals of Oncology online). The control arms of trials analysing chemotherapy included interferon, dacarbazine and other types of chemotherapy, respectively. Given the current knowledge about the effects of chemotherapy, the control arm, nowadays, likely would not have contained chemotherapy. With this analysis, we demonstrated that current guidelines are partially based on studies not powered to determine end points that show clinical benefit.
Large trials were conducted by enormous efforts of the international NET community [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . This has provided us with important data. Improvements could include trials using a preselected patient population. This is already implemented in PRRT, where somatostatin receptor-positive patients are selected for treatment [8] . Furthermore, sequential multiple assignment randomized trials can be used for hypothesis generation followed by a confirmatory RCT [21] . In addition, trials should be focused on reporting QoL and be of sufficient follow-up duration. For GEP-NET patients, use of QoL could be of additional importance because OS is generally prolonged in this cohort.
The importance of long follow-up was previously demonstrated in a trial in patients with anaplastic oligodendrogliomas. OS of adjuvant chemoradiotherapy versus radiotherapy was not improved at a median follow-up of 60 months but was improved in the chemoradiotherapy arm at a median follow-up of 140 months [22] .
International collaboration in clinical trials and investigatordriven trials should be further expanded to increase evidencebased data to support treatment decisions and lead to meaningful clinical benefit for GEP-NET patients.
Although not the aim of our analysis, we found some limitations of the tools. The ESMO-MCBS downgrades the preliminary score of a trial if no significant improvement of QoL data was shown [14] . If QoL was not reported, the preliminary score did not have to be downgraded [8, 9] .
Furthermore, we noticed during the scoring process a difference in consensus achieved by assessing trials according to the ESMO-MCBS, compared with trials assessed according to the NHB-ASCO-F. With the ESMO-MCBS, for more trials consensus was achieved. A possible reason for this is the complex toxicity data reporting according to the NHB-ASCO-F. Potentially, a clearer definition of 'clinical relevant toxicity' could facilitate the scoring. With the ASCO framework, eight clinicians completed the tool for 11 anticancer drugs. A Cohen's kappa coefficient of the interrater reliability (ICC) of 0.11 for NHB and 0.06 for toxicity was found, corresponding with 'slightly reliable agreement' [18] .
However, in another study where convergent validity and interrater reliability of assessment frameworks were analysed, the ASCO framework had an ICC of 0.80 [23] . In another report, 109 RCTs were included and ESMO scores and scores using the concept and revised version of the ASCO framework were determined. Weak to moderate correlations were demonstrated, suggesting different constructs of clinical benefit measured [24] . Other tools, used to define the value and also addressing the costs of drugs, include the National Comprehensive Cancer Network evidence blocks, Institute for Clinical and Economic Review value assessment framework and Memorial Sloan Kettering Drug Abacus [25] [26] [27] . Every tool has its own aspects. In the future, converging of tools is expected which will allow to combine the best aspects of these tools to guide policy makers and patientdoctor discussions [28] .
Conclusion
The ESMO-MCBS and the NHB of ASCO revised framework could be applied, respectively, to only six and nine trials investigating systemic treatments in NET patients. The currently used systemic treatments for GEP-NET patients had low scores according to the NHB-ASCO-F, and none could be graded as meaningful clinical beneficial according to the ESMO-MCBS. Despite the low incidence of NET, the heterogeneous patient population and the relatively long natural course, future studies on new treatment modalities should aim for high clinical benefit outcomes.
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